Ipca Laboratories Limited

Form 483 issued April 26, 2023 · Piparia, Silvassa, India

Inspection
Apr 18 – Apr 26, 2023
Observations
2
Pages
7
FEI number
3005977675

In short: On April 26, 2023, FDA issued a Form 483 with 2 observations to Ipca Laboratories Limited in Piparia, Silvassa, India (FEI 3005977675) after an inspection that ran Apr 18 – Apr 26, 2023. The investigators were Kellia N. Hicks and Rajiv R. Srivastava. Most observations concern quality system; the most-cited regulation is 21 CFR 211.192 (production record review).

At a glance

2 of 2 observations on this 483 concern quality system.

Quality system2

Most cited: 21 CFR 211.192 (1×) · 211.22 (1×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch…

  2. 02

    The responsibilities and procedures applicable to the quality control unit are not in…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Ipca Laboratories Limited?

FDA listed 2 observations on this Form 483, mostly about quality system. The most-cited regulation is 21 CFR 211.192 (production record review). The opening words of each observation are shown on this page.

Who inspected Ipca Laboratories Limited?

Kellia N. Hicks and Rajiv R. Srivastava are named on this Form 483, for the inspection of Apr 18 – Apr 26, 2023. Each investigator has a profile showing what they cite most.

When was Ipca Laboratories Limited inspected by FDA?

The inspection ran Apr 18 – Apr 26, 2023, and the Form 483 is dated April 26, 2023.

How do I get the full Form 483 for Ipca Laboratories Limited?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free